Akèy › Kansè poumon selil ti › New York › New York City
Etid klinik pou Kansè poumon selil ti nan New York City, NY
22 etid pou Kansè poumon selil ti ap chèche patisipan nan sit nan ak bò kote New York City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Columbia University Medical Center, New York
- Memorial Sloan Kettering, New York
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Memorial Sloan Kettering Cancer Center, New York
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center Head Neck Services, New York
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Ap rekriteFaz 1/2
- Avenzo Therapeutics Recruiting Site, New York
A Study of Armored CAR T Cells in People With Cancer
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Ap rekriteFaz 3
- Cornell University - NewYork-Presbyterian/Weill Cornell Medical Center, New York
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Ap rekriteFaz 1/2
- Memorial Sloan Kettering, New York
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Ap rekriteFaz 1/2
- Memorial Sloan Kettering Cancer Center (MSKCC), New York
- Icahn School of Medicine at Mount Sinai PRIME, New York
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
Ap rekriteFaz 1
- NYU Langone Health, New York
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
Ap rekriteFaz 1
- New York University Cancer Institute, New York
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
Ap rekriteFaz 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Ap rekriteFaz 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health Long Island, New York
- New York University Cancer Center - Laura and Isaac, New York
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Ap rekriteFaz 1/2
- Columbia University Medical Center - Herbert Irving Pavilion, New York
A Study of LY4175408 in Participants With Advanced Cancer
Ap rekriteFaz 1
- Columbia University, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of Hospital-at-Home for People Receiving Tarlatamab
Ap rekrite
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Lung Cancer Biomarkers and Screening
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- NYU Cancer Institute at New York University Medical Center, New York
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Ap rekriteFaz 1/2
- Weill Cornell Medicine, Cornell University (site 126), New York
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Research Site 107, New York
Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
Ap rekriteEtid obsèvasyon
- Icahn School of Medicine at Mount Sinai, New York
Etid Kansè poumon selil ti nan lòt vil
- Houston, TX26 etid
- Arlington, VA23 etid
- Boston, MA21 etid
- Los Angeles, CA20 etid
- Nashville, TN20 etid
- Orlando, FL15 etid
- Dallas, TX13 etid
- Cleveland, OH13 etid
- Chicago, IL13 etid
- St. Louis, MO13 etid
- Detroit, MI12 etid
- Washington, DC12 etid
Lòt etid nan New York City
- Kansè nan tete136 etid
- Kansè Poumon ki pa ti selil121 etid
- Kansè (tout kalite)109 etid
- Kansè pwostat103 etid
- Kansè Metastatik93 etid
- Kansè kolorektal78 etid
- Kansè ovè69 etid
- Kansè poumon60 etid
- Myelom Miltip60 etid
- Kansè pankreyas60 etid
- Kansè Endomèt52 etid
- Leksemi mieloïd egi51 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.